The occasionally discussed, but not often used, alternative hormone therapy, transdermal estrogen might be ready to soon move on to a phase III trial. A poster presentation of a phase II trial showed that transdermal estrogen patches drove down testosterone and PSA levels to a similar extent as an LHRH analog. The poster presentation was [...]
GTx announced in a company media release that it has requested that the FDA consider its new drug application (NDA) for the use of toremifene 80 mg to prevent bone fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). GTx has asked for a priority review of its application stating that “there are [...]
One of the constant questions that come up when considering whether to take intravenous bisphosphonates is the murky issue surrounding jaw or facile bone inflammation and infections. Most of us are aware of the risk and depending whom you speak with the issue is either a major problem or just a nonsense blip that will [...]
I recently met a prostate cancer survivor whose doctor prescribed a new “miracle drug” to treat his loss of bone density caused by hormone therapy. He was given a prescription for FORTEO® and told that this drug has proven itself a better alternative to bisphosphonates, the normal treatment for bone density loss. Forteo® is a [...]
According to data published in the Journal of Clinical Oncology (2008; 26:4426-34), once a week, bisphosphonate therapy improves bone density and improves turnover in prostate cancer patients with nonmetastatic disease who are on androgen deprivation therapy (ADT). A second year of bisphosphonate therapy provides additional skeletal benefit, whereas discontinuation results in bone loss and increased [...]